Hyperdiploidy Is a Common Finding in Monoclonal Gammopathy of Undetermined Significance and Monosomy 13 Is Restricted to These Hyperdiploid Patients

Purpose: Two pathways, hyperdiploid and nonhyperdiploid, are proposed for progression to plasma cell neoplasia. Implication of monosomy 13 (Δ13) is unclear in monoclonal gammopathy of undetermined significance (MGUS), and data on DNA content of plasma cells [DNA index (DI)] are rare. Experimental Design: We ascertained DI in 169 multiple myeloma (MM) and 96 MGUS patients. Interphase fluorescence in situ hybridization (FISH) coupled to cytoplasmic staining of specific Ig (cIg-FISH) was done to look for trisomies and to ascertain Δ13. Results: Hyperdiploidy and hypodiploidy were found in 54% and 11.5% of MGUS patients and in 59.5% and 25% of MM patients, respectively. In MGUS patients tested using probes for odd chromosomes, cIg-FISH showed association between trisomies for chromosomes 3, 7, 9, 11, or 15 and hyperdiploidy. Δ13 was found in 45.3% and 24.6% of MM and MGUS patients, respectively. Most Δ13 cases observed in MGUS were found within hyperdiploid clones, 38% versus 11% in hypodiploid cases, in sharp contrast with the occurrence of Δ13 in MM patients, 31.9% and 76.3%, respectively. That peculiar distribution of Δ13 according to DI persisted with other thresholds used to ascertain hyperdiploidy, such as DI ≥ 1.05. A strong relationship between IgA peak and hypodiploidy (P = 0.007) was only observed in MM, whereas λ light chain was significantly associated with hypodiploidy in MGUS (P = 0.001) and MM (P = 0.05). Hyperdiploidy shows similar pattern in MGUS and MM. Conclusion: This fits well a hyperdiploid pathway leading to MM after a preceding MGUS stage. Yet-to-be-determined secondary event(s) needs to occur for the transition to MM, unrelated to changes in chromosome number or to loss of chromosome 13. In contrast, the “nonhyperdiploid” pathway needs to be clarified further because hypodiploidy is less common in MGUS than in MM and Δ13 is rare in hypodiploid MGUS patients compared with hypodiploid MM patients.

[1]  P. Loehrer,et al.  International Staging System for Multiple Myeloma , 2006 .

[2]  G. Ahmann,et al.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. , 2005, Blood.

[3]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Magrangeas,et al.  Genetic heterogeneity in multiple myeloma , 2005, Leukemia.

[6]  F. Magrangeas,et al.  Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma , 2005, Leukemia.

[7]  U. Jäger,et al.  Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma , 2004, Leukemia.

[8]  M. Höglund,et al.  High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation , 2004, British journal of haematology.

[9]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[10]  Bart Barlogie,et al.  Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.

[11]  Gonzalez,et al.  Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. , 2003, Blood.

[12]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[13]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[14]  Martins Marta,et al.  Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia , 2003, Cancer.

[15]  R. Fonseca,et al.  Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma , 2003, Leukemia.

[16]  A. Órfão,et al.  Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. , 2003, Cancer.

[17]  R. Bataille,et al.  Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. , 2002, Blood.

[18]  G. Ahmann,et al.  Genomic abnormalities in monoclonal gammopathy of undetermined significance. , 2002, Blood.

[19]  R. Bataille,et al.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. , 2002, Blood.

[20]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[21]  C. Bastard,et al.  Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.

[22]  U. Jäger,et al.  Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance , 2000, Leukemia.

[23]  B. Barlogie,et al.  Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. , 2000, Blood.

[24]  H. Kaufmann,et al.  Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. , 2000, Blood.

[25]  R. Bataille,et al.  Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. , 1999, Blood.

[26]  R. Bataille,et al.  14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome. , 1999, Cancer research.

[27]  G. Ehninger,et al.  The incidence of DNA aneuploidy in multiple myeloma does not correlate with stage of disease. , 1998, American journal of clinical pathology.

[28]  F. Bauters,et al.  Several cytogenetic subclones may be identified within plasma cells from patients with monoclonal gammopathy of undetermined significance, both at diagnosis and during the indolent course of this condition. , 1997, Blood.

[29]  B. Barlogie,et al.  Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Cigudosa,et al.  Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations , 1997, Genes, chromosomes & cancer.

[31]  T. Facon,et al.  MULTIPLE MYELOMA: ALMOST ALL PATIENTS ARE CYTOGENETICALLY ABNORMAL , 1996, British journal of haematology.

[32]  O. Haas,et al.  Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. , 1995, Blood.

[33]  T. Facon,et al.  Monoclonal gammopathy of undetermined significance: chromosome changes are a common finding within bone marrow plasma cells , 1995, British journal of haematology.

[34]  J. Miguel,et al.  Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients , 1995, British journal of haematology.

[35]  J. Mary,et al.  Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. , 1995, Blood.

[36]  F. Bauters,et al.  Image analysis in multiple myeloma at diagnosis. Correlation with cytogenetic study. , 1994, Cancer genetics and cytogenetics.

[37]  A. Tienhaara,et al.  Flow cytometric DNA analysis and clinical correlations in multiple myeloma. , 1992, American journal of clinical pathology.

[38]  J. Drach,et al.  The biological and clinical significance of the KI‐67 growth fraction in multiple myeloma , 1992, Hematological oncology.

[39]  G. Mazzini,et al.  Ras oncogene expression and DNA content in plasma cell dyscrasias: a flow cytofluorimetric study. , 1990, British Journal of Cancer.

[40]  B. Barlogie,et al.  Ploidy and proliferative characteristics in monoclonal gammopathies. , 1982, Blood.